Antiretrovirals and other stuff!
11 February 2006. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Understanding TMC114 power against resistant HIV
10 February 2006. Related: Conference reports, Antiretrovirals.
New antiretroviral compounds at ICAAC: new PI brecanavir from GSK; maturation inhibitor PA-457; antiviral activity of monoclonal antibody; TNX-355 in treatment experienced patients
10 February 2006. Related: Conference reports, Antiretrovirals.
Three measures confirm 144-week renal record of tenofovir
10 February 2006. Related: Conference reports, Antiretrovirals.
Low rash risk with efavirenz after nevirapine rash
10 February 2006. Related: Conference reports, Antiretrovirals.
SMART study halted due to safety concerns with significantly more AIDS events in the treatment interruption arm
9 February 2006. Related: Antiretrovirals.
TMC114 (darunavir) new drug applications submitted to US and European regulatory agencies
9 February 2006. Related: Antiretrovirals.
Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114)
13 December 2005. Related: Antiretrovirals.
Tibotec discontinues TMC125 study C227: phase III studies continue
13 December 2005. Related: Antiretrovirals.
New Kaletra tablet formulation (meltrex) approved by FDA
13 December 2005. Related: Antiretrovirals.
GSK closes phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme
13 December 2005. Related: Antiretrovirals.
Schering discontinues phase 2 studies of vicriviroc in treatment naive patients
13 December 2005. Related: Antiretrovirals.
FDA issues approvable letter for Bioject needle-free injection device
13 December 2005. Related: Antiretrovirals.
Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)
13 December 2005. Related: Antiretrovirals, Treatment strategies.
GSK stops trials of CCR5 entry inhibitor GW873140 in naive patients
13 October 2005. Related: Antiretrovirals.
AZT comes off patent: generic versions approved for US market
13 October 2005. Related: Antiretrovirals.
Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results
14 September 2005. Related: Conference reports, Antiretrovirals.
Strategies for salvage therapy
14 September 2005. Related: Conference reports, Antiretrovirals.
Antiviral activity of foscarnet in salvage patients
14 September 2005. Related: Conference reports, Antiretrovirals.
Novel strategies with existing drugs
14 September 2005. Related: Conference reports, Antiretrovirals.
Antiretroviral activity of new and novel agents
14 September 2005. Related: Conference reports, Antiretrovirals.
FDA filing of T-20 sNDA for administration with a needle-free injection device
14 August 2005. Related: Antiretrovirals.
Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs
14 July 2005. Related: Conference reports, Antiretrovirals.
TMC-114 to be submitted for registration based on Phase 2b trial results: expanded access expected in UK in Autumn 2005
14 July 2005. Related: Antiretrovirals.
Tipranavir (Aptivus) approved in US
14 July 2005. Related: Antiretrovirals.
FDA fast track designation for CCR5 inhibitor vicriviroc (SCH-D)
14 July 2005. Related: Antiretrovirals.
Pfizer discontinues development of capravirine
14 July 2005. Related: Antiretrovirals.
Effect of age on lopinavir concentrations
15 June 2005. Related: Conference reports, Antiretrovirals.
Gender and pharmacokinetics of saquinavir
15 June 2005. Related: Conference reports, Antiretrovirals.
Responses to atazanavir, Kaletra and side effects
15 June 2005. Related: Conference reports, Antiretrovirals.
500mg saquinavir (Invirase) approved in Europe
15 June 2005. Related: Antiretrovirals.
Roche to withdraw saquinavir soft gel caps (Fortovase)
15 June 2005. Related: Antiretrovirals.
FDA approve lopinavir/r once daily for treatment naive patients
15 June 2005. Related: Antiretrovirals.
Safety data for tenofovir updated
15 June 2005. Related: Antiretrovirals.
FDA approve entecavir for HBV
15 June 2005. Related: Antiretrovirals.
Efavirenz warning in pregnancy strengthened
15 June 2005. Related: Antiretrovirals.
New ritonavir interactions
15 June 2005. Related: Antiretrovirals.
FDA advisory committee recommends approval for tipranavir – material from hearing online
15 June 2005. Related: Antiretrovirals.
Application for meltrex formulation of Kaletra submitted to the FDA
15 June 2005. Related: Antiretrovirals.
24-week efficacy of TMC114 in PI-experienced patients
18 April 2005. Related: Conference reports, Antiretrovirals.
Maturation inhibitor shows anti-HIV activity in single dose pilot study
18 April 2005. Related: Conference reports, Antiretrovirals.
New antiretrovirals at 12th CROI
18 April 2005. Related: Conference reports, Antiretrovirals.
500mg saquinavir (Invirase) approved in Europe
18 April 2005. Related: Antiretrovirals.
Roche discontinue ddC and Fortovase
18 April 2005. Related: Antiretrovirals.
Needle-free injections for T-20 in US
18 April 2005. Related: Antiretrovirals.
Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen
29 March 2005. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM
29 March 2005. Related: Conference reports, Antiretrovirals.
Effective switching to atazanavir/ritonavir in clinical practice
29 March 2005. Related: Conference reports, Antiretrovirals.
Ritonavir boosting may not overcome interaction between atazanavir and nevirapine
29 March 2005. Related: Conference reports, Antiretrovirals.
TDM in Ugandan study highlights importance of refridgerated ritonavir
29 March 2005. Related: Conference reports, Antiretrovirals.
Lower d4T dose maintains virologic suppression and CD4 increases
29 March 2005. Related: Conference reports, Antiretrovirals.
Widespread adoption of post exposure prophylaxis (PEP) recommended in US
29 March 2005. Related: Antiretrovirals.
European Approval For Kivexa (abacavir/3TC)
29 March 2005. Related: Antiretrovirals.
500 mg saquinavir (Invirase) approved in US
29 March 2005. Related: Antiretrovirals.
Indinavir not recommended in pregnancy due to reduced pharmacokinetic levels
29 March 2005. Related: Antiretrovirals, Pregnancy.
25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’
31 January 2005. Related: Conference reports, Antiretrovirals.
Indinavir impairs endothelial function without insulin resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Tipranavir in treatment experienced patients: results from RESIST-1
31 January 2005. Related: Conference reports, Antiretrovirals.
Reverset: first data in patients with nucleoside resistance
31 January 2005. Related: Conference reports, Antiretrovirals.
Poor response with tenofovir and ddI backbone causes early study termination
31 January 2005. Related: Conference reports, Antiretrovirals.
Paradoxical CD4 response with tenofovir and ddI backbone
29 January 2005. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy
29 January 2005. Related: Conference reports, Antiretrovirals.
Limited stability of lopinavir/r (Kaletra) above 25°C
29 January 2005. Related: Conference reports, Antiretrovirals.
Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
29 January 2005. Related: Conference reports, Antiretrovirals.
Further genetic link to efavirenz absorption
29 January 2005. Related: Conference reports, Antiretrovirals.